CureSHANK Community News: MARCH 2026

This month, we’re sharing meaningful momentum across the PMS and SHANK3 community. From the launch of the first gene therapy clinical trial for SHANK3 deficiency to new tools accelerating therapeutic development — including our newly developed SHANK3 mouse model — progress is underway on multiple fronts. We’re also looking ahead to our third annual PMS Drug Development Symposium this April in New York, where leaders in science, industry, and investment will come together to move the field forward.

You’ll also find updates from Rare Disease Day at NIH, opportunities to support Start Genetic and Team CureSHANK at the L.A. Marathon, active clinical trials and research studies, and new funding opportunities for researchers and companies working to advance treatments.

As always, get the full story here.